文献速递妇科

韩国随机对照III期试验中III-IV期卵巢癌间歇性肿瘤细胞减灭术后腹腔热灌注化疗的成本效果

Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01).
PubMed 文献 · Gynecol Oncol · 2023-01-04

基于韩国随机对照III期试验(KOV-HIPEC-01),采用Markov模型评估间歇性肿瘤细胞减灭术(ICS)后腹腔热灌注化疗(HIPEC)的成本效果,时间跨度10年,视角为韩国医疗体系。结果显示ICS+HIPEC组平均QALY为10.8,ICS组为7.16,增量QALY为3.64,ICER为954,598韩元(708.3美元)/QALY。作者认为ICS后HIPEC具有成本效果,可支持韩国医保报销。

要点

  • ICS+HIPEC组平均QALY为10.8,ICS组为7.16,增量QALY为3.64。
  • ICER为954,598韩元(708.3美元)/QALY,作者认为具有成本效果。
  • 结果可能支持韩国医保对HIPEC的报销及长期管理。

核心结论

  • 研究结果表明,ICS后行HIPEC具有成本效果,QALY增益显著。
  • 这些结果可能支持韩国医保对HIPEC的现行报销及长期疾病管理。

研究设计与样本

  • 基于随机对照III期试验(KOV-HIPEC-01,NCT01091636)队列数据的比较性成本效果分析。
  • 采用Markov健康状态转换模型,时间跨度为10年,成本从韩国医疗体系角度计算,健康效用值取自已发表来源。

主要发现

  • ICS组平均QALY为7.16,ICS后HIPEC组为10.8。
  • 增量QALY为3.64,ICER为954,598韩元(708.3美元)/QALY。

临床怎么用

  • 作者认为ICS后HIPEC具有成本效果,可支持韩国医保报销决策。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate the cost-effectiveness of the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) following interval cytoreductive surgery (ICS) for stage III-IV ovarian cancer from a randomized controlled phase III trial. METHODS: A comparative cost-effective analysis was performed using a Markov health-state transition model derived from the current trial cohort (ClinicalTrials.gov Identifier: NCT01091636). The incremental cost-effectiveness ratio (ICER) was evaluated by dividing the incremental costs by incremental quality-adjusted life-years (QALYs) with a time horizon of 10 years. Costs were calculated from the perspective of Korean healthcare, and health utility values were extracted from published sources. RESULTS: Based on data from the trial, the mean QALY in the ICS group was 7.16 compared to 10.8 in ICS followed by the HIPEC group. With an incremental QALY of 3.64, the ICS followed by HIPEC, was estimated to obtain an ICER of KRW 954,598 (USD 708.3) per QALY. CONCLUSION: The findings of the study suggest that ICS followed by HIPEC, is cost-effective with a significant gain in QALYs. These results may support the current reimbursement of HIPEC from Korean insurance services and the management of long-term conditions.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kim JH, Chun SY, Lee DE, et al. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01). Gynecol Oncol. 2023. PMID: 36608383. doi:10.1016/j.ygyno.2022.12.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。